BSH 2024 | The novel bioactive peptide QUB-2392 shows anti-leukemic effects in leukemia cell lines
Ruth Gyereh, PhD, London South Bank University, London, UK, provides an insight into an investigation of the novel bioactive peptide QUB-2392, which was shown to have anti-leukemic effects when tested on leukemia cell lines. Through proteomics and gene profiling, Dr Gyereh and her team observed the upregulation of pro-apoptotic proteins and tumor suppressors and the down-regulation of several oncogenes. As the peptide was found to have immunomodulatory and anti-proliferative effects, it will be investigated in further studies. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
